Paradox Immunotherapeutics, a Toronto, Canada-based pharmaceutical company focused on the development of antibody therapies, received a $10M investment from SymBiosis Capital Management.
In connection with the funding, Sandy Zweifach, an Operating Advisor at SymBiosis, recently joined Paradox as an independent director and Executive Chairman.
The company intends to use the funds to advance its therapeutic pipeline through advancements in multiple indications.
Led by CEO Dr. Natalie Galant, Paradox is a preclinical-stage biotech that uses a drug discovery platform to combat protein misfolding diseases such as amyloidosis. It is focused on the development of treatment for immunoglobulin light chain amyloidosis (AL amyloidosis), a complication of multiple myeloma that can lead to heart, kidney and liver failure, as well as treatment for leukocyte chemotactic factor 2 amyloidosis (LECT2), a severely underdiagnosed cause of chronic kidney disease and failure.
FinSMEs